Resonance Health (RHT.AX) Osake Kurssi

Resonance Health Ltd is primarily active in the healthcare and medical technology industries.

The main competitors of Resonance Health Ltd in the market include other companies operating in the medical diagnostics and healthcare sector. Some prominent competitors are InHealth Group, Q BioMed, and Novartis AG. Resonance Health Ltd faces competition from these companies in developing innovative diagnostic solutions and providing high-quality healthcare services.

Resonance Health Ltd. is a leading provider of automated, non-invasive medical imaging software and analysis services. Founded in 1987, the company has a rich history of innovation and expertise in the field of liver and cardiac MRI imaging. Resonance Health's technology allows for accurate and reliable diagnosis of liver iron concentration and cardiac ejection fraction, essential measurements for monitoring patients with iron overload and heart conditions. With a strong commitment to research and development, Resonance Health continues to develop cutting-edge solutions that improve patient outcomes and streamline healthcare processes. As a trusted name in the industry, Resonance Health Ltd. has gained recognition globally for its advanced medical imaging products and services.

Resonance Health Ltd, a leading company in the healthcare sector, has accomplished several significant milestones. One noteworthy achievement is the development of FerriScan®, an advanced diagnostic tool for measuring liver iron concentration. Through extensive research and innovative technology, Resonance Health Ltd has revolutionized the diagnosis and monitoring of iron overload disorders such as hereditary hemochromatosis and thalassemia. The company has also expanded its global presence by establishing partnerships with renowned medical institutions and securing regulatory approvals for its groundbreaking products. With a relentless commitment to advancing patient care, Resonance Health Ltd continues to make remarkable strides in the field of medical diagnostics.

Resonance Health Ltd is primarily present in multiple countries and regions across the world. With its global reach, the company has established a strong presence in key markets. Its operations span across Australia, the United States, Europe, and Asia-Pacific regions. Resonance Health Ltd's commitment to expanding its footprint internationally has enabled it to serve a diverse range of customers and collaborate with partners on a global scale. This global presence reinforces Resonance Health Ltd's position as a leading player in the industry while allowing it to leverage various market opportunities and better serve its stakeholders.

Resonance Health Ltd represents values of innovation, excellence, and integrity in its corporate philosophy. As a leading stock health company, Resonance Health Ltd focuses on utilizing advanced technology and research to improve the diagnosis and treatment of liver diseases and iron disorders. With a dedicated team of experts, the company prioritizes accuracy and efficiency in its solutions, delivering reliable results to healthcare professionals worldwide. Resonance Health Ltd strives to enhance patient care by providing precise diagnostic tools, earning recognition for its commitment to quality and advancing medical knowledge.

Nykyisellä valuuttakurssilla Resonance Health-osake noteerataan hintaan 0,05 EUR (0,08 AUD).

Resonance Health-osake (RHT.AX) on listattuna 1 pörssissä, muun muassa: ASX (RHT.AX).

Resonance Health Ltd is a medical technology and software company specializing in the development and marketing of medical imaging devices, software, and services. The company is based in Perth, Australia, and operates worldwide.

liikevaihto Resonance Health on 15,75 M AUD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

voitto Resonance Health on 1,51 M AUD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Resonance Health:n hinta-voitto-suhde (P/E) on tällä hetkellä 23,93. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Resonance Health-osakkeen arvostusta.

Resonance Health:n hinta-myynti-suhde (P/S) on tällä hetkellä 2,30. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Resonance Health-osakkeen arvostuskennuslukuna.

Resonance Health:n Eulpool-laatuscore on 6/10.

Resonance Health:n ISIN on AU000000RHT2. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Resonance Health:n WKN on A0BK8V. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Resonance Health:n ticker on RHT.AX. Tämä pörssinoteeraus käytetään Resonance Health-osakkeiden kauppaan pörssissä.